Squarepoint Ops LLC Purchases 38,524 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Squarepoint Ops LLC boosted its position in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 101.3% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 76,539 shares of the company’s stock after purchasing an additional 38,524 shares during the period. Squarepoint Ops LLC’s holdings in Ventyx Biosciences were worth $177,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Ventyx Biosciences by 66.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,385 shares of the company’s stock valued at $63,000 after purchasing an additional 4,553 shares during the last quarter. Norden Group LLC bought a new position in shares of Ventyx Biosciences in the first quarter worth about $59,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Ventyx Biosciences in the first quarter worth about $72,000. SG Americas Securities LLC bought a new position in shares of Ventyx Biosciences in the second quarter worth about $32,000. Finally, Rhumbline Advisers raised its stake in shares of Ventyx Biosciences by 38.0% in the second quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock worth $209,000 after acquiring an additional 24,885 shares during the last quarter. 97.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

VTYX has been the subject of a number of research analyst reports. Canaccord Genuity Group dropped their target price on shares of Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 target price on shares of Ventyx Biosciences in a research note on Monday, September 23rd. Finally, Wells Fargo & Company dropped their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Ventyx Biosciences has an average rating of “Moderate Buy” and a consensus price target of $8.29.

Ventyx Biosciences Trading Up 4.4 %

Shares of VTYX opened at $2.14 on Monday. Ventyx Biosciences, Inc. has a 12 month low of $1.79 and a 12 month high of $20.39. The firm has a fifty day simple moving average of $2.15 and a 200 day simple moving average of $3.19. The stock has a market capitalization of $151.23 million, a price-to-earnings ratio of -0.77 and a beta of 0.36.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. As a group, research analysts predict that Ventyx Biosciences, Inc. will post -2.14 earnings per share for the current fiscal year.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.